Your AI-Trained Oncology Knowledge Connection!
Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.
Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.
Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery.
Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.
Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.
Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.
Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.
John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.
A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.
John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.
John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.
Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.
Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.
Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.
Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.
Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.
Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.
Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.
Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.
David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.
Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.
Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.
David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.
The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.
John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.
Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.
David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.
